Global Alpha 1 Antitrypsin Deficiency Treatment Market Report, Industry Trends, Size, Share, Regional Breakup and Forecast Till 2025
According to IMARC Group’s latest report, titled “Alpha 1 Antitrypsin Deficiency Treatment Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025,” the global alpha 1 antitrypsin deficiency treatment market to continue its strong growth during the next five years. Alpha-1 antitrypsin (AAT) deficiency is a genetic disorder due to which the body does not generate sufficient AAT protein. AAT proteins protect the lungs and liver from the adverse effects of other proteins present in the body. Patients with AAT deficiency are prone to numerous medical ailments, including liver cirrhosis, chronic obstructive pulmonary diseases (COPD), etc. A genetic or blood test can detect the AAT protein deficiency, which can be further treated by pulmonary rehabilitation, augmentation, and oxygen therapy. Furthermore, treatment procedures mainly involve the administration of medicines, such as bronchodilators and corticosteroids.
Request Free Sample Report: https://www.imarcgroup.com/alpha-1-antitrypsin-deficiency-treatment-market/requestsample
Market Trends
The rising occurrence of respiratory disorders, due to the increasing air pollution levels and high consumption of tobacco products, is primarily driving the market growth. Besides this, the widespread utilization of augmentation therapy for improving the recovery speed of patients, reducing the frequency of exacerbations, delaying emphysema progression, etc., is also driving the market. Moreover, several advancements in the diagnostic methods, along with the development of innovative processes for the production and purification of AAT, are further catalyzing the global market. Alpha 1 Antitrypsin Deficiency Treatment Market 2020-2025 Analysis and Segmentation:
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these key players include:
- AstraZeneca PLC
- Boehringer Ingelheim GmbH
- CSL Limited
- GlaxoSmithKline Plc
- Grifols S.A.
- Kamada Ltd.
- LFB Biomedicaments
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
The report has segmented the market on the basis of treatment type, route of administration, end-user and region.
Breakup by Treatment Type:
- Augmentation Therapy
- Bronchodilators
- Corticosteroids
- Oxygen Therapy
- Others
Breakup by Route of Administration:
- Parenteral
- Inhalation
- Oral
Breakup by End User:
- Hospitals
- Specialty Clinics
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/alpha-1-antitrypsin-deficiency-treatment-market
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us
IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Website: https://www.imarcgroup.com/
Email: sales@imarcgroup.com
USA: +1-631-791-1145
Follow us on twitter: @imarcglobal
Linkedin: https://www.linkedin.com/company/imarc-group
